Oral proteasome inhibitor with strong preclinical efficacy in myeloma models

The proteasome is a validated anti-cancer target and various small-molecule inhibitors are currently in clinical development or on the market. However, adverse events and resistance associated with those proteasome inhibitors indicate the need for a new generation of drugs. Therefore, we focused on...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMC cancer 2016-03, Vol.16 (1), p.247-247, Article 247
Hauptverfasser:	Park, Jonghoon, Park, Eok, Jung, Cheol-Kyu, Kang, Seung-Wan, Kim, Byung Gyu, Jung, Youngjoo, Kim, Tae Hun, Lim, Ji-Young, Lee, Sung-Eun, Min, Chang-Ki, Won, Kwang-Ai
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Animals Antineoplastic Agents - administration & dosage Apoptosis Apoptosis - drug effects Bioavailability Boron Compounds - administration & dosage Bortezomib - administration & dosage Cancer Cell cycle Cell Line, Tumor Cell Proliferation - drug effects Cell Survival - drug effects Drug Resistance, Neoplasm - drug effects Drug Resistance, Neoplasm - genetics Drug Synergism Drug therapy Enzymes Female Glycine - administration & dosage Glycine - analogs & derivatives Humans Life sciences Male Mice Middle Aged Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - pathology Oligopeptides - administration & dosage Oral medication Patient outcomes Penicillin Proteasome Endopeptidase Complex - drug effects Proteasome Inhibitors - administration & dosage Review boards Signal transduction Thalidomide - administration & dosage Thalidomide - analogs & derivatives Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!